logo
Review: 'Doom: The Dark Ages' reinvents run-and-gun formula … again

Review: 'Doom: The Dark Ages' reinvents run-and-gun formula … again

The Stara day ago

LOS ANGELES: The rebooted Doom series has been a masterclass in reinvention. Bucking the trend of military shooters, the id Software team crafted a brilliant gameplay loop that's the spiritual successor to the run-and-gun action the developers pioneered in 1993.
It relied on movement, herding enemies and creating satisfying combo-based combat while introducing exploratory elements. The sequel Doom Eternal refined that formula, emphasising vertical gameplay that made the Doom Slayer protagonist feel like a fighter jet, according to game director Hugo Martin. The third entry for the reboot goes in a different direction.
A vision that works
Doom: The Dark Ages is a prequel to the first two games and lets players discover the events leading up to the original reboot. It finds the Doom Slayer as a tool of the Maykrs as he's deployed to help the Sentinels in their battle against the minions of hell.
Over the course of 22 levels, players will be in the heart of the Argenta Unholy Wars' politics and drama as the villain Prince Ahzrak searches for the Heart of Argent, a power capable of making him a god. He and his hell minions attack the Sentinels, who are hiding that power and trying to keep it out of his hands.
The beauty of The Dark Ages is that players don't need to know much about the past games. They can jump into this chapter and enjoy the spectacle of seeing the Doom Slayer become the ultimate demon-fighting machine.
When playing The Dark Ages , veterans will notice that this version of the Doom Slayer is a different beast from the past games. Developers at id Software revamped the combat to emphasise a more ground-based approach. If Doom Eternal made players feel like a jet pilot, The Dark Ages will make them think they're controlling a zippy modern tank.
Most of the combat revolves around a shield that can deflect attacks and protect against projectiles while dicing fodder with a Captain America-like throw. Further in the campaign, the shield is imbued with runes that give it other ways to attack. Aside from offence, the shield also has a role in exploration, with players using it almost like a grappling hook at certain nodes. They can also crash through weakened walls or destroy pulleys that hold doors shut.
It's a simple tool that's controlled by two buttons, but id Software does a remarkable job of giving it versatility, so that it can do much more, especially when combined with weapons.
Weapon versatility
The Dark Ages has an arsenal with enough versatility that players won't be leaning on two weapons. The fan favourite Super Shotgun can handle a wide range of encounters, but the Doom Slayer will encounter enemies that move too quickly or have attacks that take advantage of its limited range. That's when players will have to rely on other weapons and their properties, which emerge when they're powered up at the Sentinel Shrine.
The team at id smartly crafted weapons to encourage players to switch them up, depending on the circumstances. If players need to stun enemies, the Cycler can shock swarming adversaries, giving players the opportunity to thin the herd. The Rocket Launcher has the ability to regain health when players parry an attack and enter the splash damage zone. Combine this with the melee weapon and shield rune upgrades, and players have several strategies to survive the demon horde onslaught.
The weapons and shield forge a fascinating offshoot from the combat of the first two games. It's ground-based but manages to feel fast while satisfying players' desire to combo attacks, showing off the Doom Slayer's maneuverability. The gameplay echoes the original Doom titles that reward players who can circle strafe around attacks and dodge the shower of projectiles that flash across the screen.
In The Dark Ages , series veterans do the same thing, albeit with a bigger arsenal and solid defensive moves that make dodging unnecessary.
In fact, the campaign has moments where it feels as though the Doom Slayer is slugging it out with Cyber Demons, trading blows while blocking the enemy's melee attacks. At times, combat is essentially a heavyweight prize fight in mid-fisticuffs.
A flow state
The developers mix up the main gameplay with levels, in which players control an enormous mech called an Atlan and pilot a dragon named Serrat. The giant robot action gives players a sense of scale in these battles where they fight enormous demons mainly with melee attacks. The simple fighting mechanics work as the behemoths don't have much in terms of subtlety of movement.
Meanwhile, the dragon levels are less successful but still exhilarating. Flying Serrat is more complicated than controlling the mech and requires a different set of skills. Players have to locate aircraft and shoot them down while also locking in on other adversaries, while dodging attacks, in order to blast them away.
The developers do a notable job of mixing these elements of play through the campaign. For example, players fly their dragon and take down a massive enemy hell-icarrier (for lack of a better word) and they can land Serrat atop the vehicle, enter it and wipe out the enemies inside.
All of this flows remarkably well, and that's the driving force behind the gameplay. Amid the whirlwind of extreme violence, The Dark Ages builds a momentum in its level design and pushes players along. And though it has secrets and rewards exploration, the team lays out these secrets in way that keeps propelling the Doom Slayer forward.
In other words, it's a game that keeps the energy going forward and doesn't stop until its epic conclusion. – The Mercury News/Tribune News Service

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Prem clubs set to spend big this week as Man Utd close in on Mbeumo transfer
Prem clubs set to spend big this week as Man Utd close in on Mbeumo transfer

Daily Mirror

time22 minutes ago

  • Daily Mirror

Prem clubs set to spend big this week as Man Utd close in on Mbeumo transfer

Premier League clubs could ramp up their summer spending starting on Tuesday, as they enter a new accounting year which means they are not as restricted by the Profit and Sustainability Rules The transfer window is set to hot up with Premier League clubs waiting for this week until they ramp up their recruitment, as they hold fire until the next year of accounts. We've just entered the new reporting year under the Premier League's financial rules and it means any deals can now be posted on the 2025/26 accounts, rather than those from 2024/25. Any clubs who were on the limit of this year's Profit and Sustainability Rules (PSR) may have been holding fire on a number of transfers. ‌ The powers that be have already shown that breaching PSR rules can result in points deductions and some teams had been putting their business on pause to avoid adding any numbers to their 2024/25 balance sheet, reports the Daily Mail. ‌ But anything from Tuesday onwards will go against a new account, where clubs will have a lot more room for manoeuvre. As a result spending is likely to ramp up. This summer we have already seen the British-record transfer broken by Liverpool, who have spent close to £200million to land the likes of Florian Wirtz, Jeremie Frimpong and Milos Kerkez. That said, the Reds hardly spent anything last summer so will have had the room to invest. Manchester United spent £62.5m to add Matheus Cunha but he is their only summer signing thus far despite their pursuit of Bryan Mbeumo. They've had several offers for the Brentford man rejected but the deal is expected to get over the line. Manchester City have added three new faces with Rayan Cherki among them. Pep Guardiola is eyeing a rebuild and their summer recruitment will be aided by the millions they receive from the Club World Cup, where they have advanced to the knockout stages. Newcastle have been somewhat hampered by PSR in the past but this new accounting year could give them space to invest. They're going after Brighton's Joao Pedro whilst they have also expressed their interest in goalkeeper James Trafford and Nottingham Forest's Anthony Elanga. Arsenal are expected to sign a striker this summer but nothing has been confirmed yet with Benjamin Sesko and Viktor Gyokeres on their radar. They've also not official announced the signing of Martin Zubimendi from Real Sociedad. Join our new WhatsApp community and receive your daily dose of Mirror Football content. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. If you're curious, you can read our Privacy Notice.

argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes

Yahoo

time22 minutes ago

  • Yahoo

argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes

Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP), argenx's collaborative discovery model June 30, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its plan to advance the clinical development of ARGX-119, a first-in-class agonist antibody to muscle-specific kinase (MuSK), to a registrational study in patients with congenital myasthenic syndromes (CMS) following the analysis of topline data from the Phase 1b study. Detailed results will be presented at a future medical meeting. 'The results of our Phase 1b ARGX-119 study in congenital myasthenic syndromes, an ultra-rare disorder that affects patients from birth, builds on our experience and understanding of myasthenic disorders and aligns with our aspiration to serve even more patients living with these debilitating diseases,' said Luc Truyen, M.D., Ph.D., Chief Medical Officer of argenx. 'ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept, reflecting the strength of our innovation model where our deep knowledge of the biology and expertise in antibody engineering come together to push the boundaries of what's possible. argenx remains focused on uncovering new biological insights into misunderstood diseases to meaningfully change the lives of patients who have long-been underserved,' said Peter Ulrichts, Ph.D., Chief Scientific Officer of argenx. The decision to advance the development of ARGX-119 in CMS is supported by the results of the Phase 1b study. ARGX-119 demonstrated a favorable safety and tolerability profile, which was the primary endpoint. Efficacy was evaluated across multiple secondary and exploratory endpoints, including Six-Minute Walk Test (6MWT), Quantitative Myasthenia Gravis (QMG) score and Myasthenia Gravis Activities of Daily Living (MG-ADL) score. Consistent improvements were observed in treated DOK7-CMS patients through the 12-week study across multiple efficacy scores. Phase 1b CMS Study Design The Phase 1b, multicenter, randomized, double-blinded, placebo-controlled clinical trial assessed safety, tolerability, PK, immunogenicity, and preliminary efficacy of ARGX-119 in participants with DOK7-CMS. The study was also designed to demonstrate proof-of-biology through preliminary efficacy assessments, including muscle weakness, fatigability, daily activities and patient-reported global health outcomes. The clinical trial spanned approximately 11 months across a screening period (up to 28 days), a 12-week treatment period and a follow-up period of nearly seven months. At baseline, eligible participants were randomized 4:1 to receive intravenous ARGX-119 or placebo. The primary objective was to evaluate safety and tolerability; secondary objectives included PK, immunogenicity and preliminary efficacy of ARGX-119 in participants with DOK7-CMS. All but one of the patients enrolled in the Phase 1b study also participated in an observational natural history study initiated by argenx in 2024 to better understand the CMS patient journey and disease burden, helping to inform future development plans. About Congenital Myasthenic Syndromes Congenital Myasthenic Syndromes (CMS) are an ultra-rare and heterogenous group of congenital neuromuscular disorders caused by genetic defects that are essential for the integrity of the neuromuscular junction. Early age of onset and fatigable muscle weakness are considered clinical hallmarks of CMS. Muscle weakness can be debilitating and life-threatening causing difficulties in speaking or swallowing, impaired or absent mobility, proximal arm and leg weakness, and respiratory insufficiency. DOK7 variations are one of the more frequent and severe causes of CMS, accounting for approximately 24% of CMS cases. There are no approved treatments. The prevalence of CMS is estimated to be 5 per 1M (DOK7-CMS estimated to be 1.2 per 1M). About ARGX-119 ARGX-119 is a first-in-class humanized agonist monoclonal antibody (mAb) that specifically targets and activates muscle-specific tyrosine kinase (MuSK) to promote maturation and stabilization of the neuromuscular junction (NMJ). It is a mAb derived from llamas and discovered using the argenx SIMPLE Antibody™ platform technology. ARGX-119 is being developed for patients with neuromuscular disease, including congenital myasthenic syndromes (CMS), amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). ARGX-119 was developed through argenx's IIP program in collaboration with the world's leading key opinion leaders on MuSK and the NMJ, Professor Steven J. Burden from MGH, Professor Shohei Koide from NYU and Professor Jan Verschuuren and Associate Professor Maartje Huijbers from LUMC. About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, Instagram, Facebook, and YouTube. Media: Colin McBeancmcbean@ Investors: Alexandra Roy aroy@ Forward Looking Statements The contents of this announcement include statements that are, or may be deemed to be, 'forward looking statements.' These forward-looking statements can be identified by the use of forward-looking terminology, including the terms 'aims,' 'committed,' or 'plan' and include statements argenx makes concerning its commitment to improving the lives of people suffering from severe autoimmune diseases; its plan to advance the clinical development of ARGX-119 to a registrational study in CMS patients; and its goal of translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx's clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements; the acceptance of its products and product candidates by its patients as safe, effective and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; its reliance on third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Tabreed and CVC DIF to acquire Abu Dhabi's PAL Cooling from Multiply Group
Tabreed and CVC DIF to acquire Abu Dhabi's PAL Cooling from Multiply Group

Al Bawaba

time23 minutes ago

  • Al Bawaba

Tabreed and CVC DIF to acquire Abu Dhabi's PAL Cooling from Multiply Group

CVC DIF, the infrastructure strategy of leading global private markets manager, CVC, and Tabreed, the world's leading district cooling company, have entered a partnership to acquire PAL Cooling Holding from Abu Dhabi's Multiply Group. The transaction, with an equity value of approximately AED 3.8 billion, includes three long-term concessions in the Abu Dhabi main island area and five long-term concessions on Al Reem Island, and remains subject to customary regulatory approvals. The concessions are serviced by five existing, sustainable district cooling plants and associated networks in Abu Dhabi, with connected capacity of 182,000 refrigeration tons (RT) as of December 2024. An additional plant is currently under construction and three more are in the planning phase. Together the nine plants and eight concessions are expected to represent approximately 600,000 RT. PAL was founded in 2006 and is a prominent player in the UAE district cooling market, catering to landmark residential, commercial and mixed-use developments. The company has eight, long-term concession agreements and partnerships with leading master developers, including Aldar Properties, Modon and Imkan. PAL is strongly positioned on Al Reem Island, which is a strategic destination now fully part of the ADGM free zone, the vibrant financial centre of Abu Dhabi, and is poised to benefit from the expected development ramp-up, with future network expansion already licenced by Abu Dhabi's Department of Energy. Chairman of Tabreed, Dr Bakheet Al Katheeri, emphasised the significance of the partnership: 'Tabreed is always looking to the future and ensuring we remain agile. The acquisition of PAL Cooling with CVC DIF aligns perfectly with our strategic objectives and readiness to adapt to Abu Dhabi's ambitious real estate projects. This year has been historic for Tabreed, with ventures like our Palm Jebel Ali JV and continued growth in Abu Dhabi. These steps position us to meet the UAE's rising demand for sustainable cooling, driven by population growth and decarbonisation targets.' Gijs Voskuyl, Managing Partner at CVC DIF, said: 'PAL Cooling services its clients under long-term, concession-based contracts, in a fast-growing urban environment. The company has a strong track record of developing and constructing high-quality and electrified district cooling plants to deliver reliable, energy-efficient cooling solutions. Building on CVC DIF's long-term track record in the sector, we are delighted to partner with Tabreed, a leading district cooling company in the Middle East. Together with our partners, we are convinced that PAL Cooling is a high-quality investment that will provide our investors with solid returns, while offering the potential for long-term growth and sustainable value creation.' Chief Executive Officer of Tabreed, Khalid Al Marzooqi, added: 'This is turning out to be a truly pivotal year for Tabreed. As we enter a new phase of growth in Abu Dhabi alongside partners, CVC DIF, the benefits brought by this acquisition will be substantial. As part of Tabreed's portfolio, these additional plants will be operated and maintained by the world's leading experts in sustainable cooling. The acquisition also serves to strengthen our already investment-grade status with safe, long-term concession agreements and assured future growth, evidenced by current and planned developments on Reem Island.' Özgür Önder, Head of CVC Middle East, said: 'Our partnership with Tabreed, a regional leader with deep industry expertise, aligns perfectly with CVC's commitment to investing in the UAE, backing mission-critical businesses that support sustainable development across the country.' CVC DIF's investment focus and experience spans key sectors including Energy Transition, Digital Infrastructure, Utilities and Transport – areas that are critical to Tabreed's strategic vision. Its expertise and investment approach makes CVC DIF an ideal partner for a transformative project of this scale. Commenting on the transaction, Samia Bouazza, Group CEO and Managing Director of Multiply Group, said: 'The monetisation of PAL Cooling Holding is a deliberate step in our portfolio optimisation strategy, aimed at delivering superior returns to our shareholders. It reflects our ability to realise significant value from our assets while enhancing liquidity to fuel Multiply Group's next phase of growth – both across our core verticals and on the global stage.' The deal was signed during a special ceremony at Multiply's Abu Dhabi headquarters by Samia Bouazza, Group CEO and Managing Director of Multiply Group, Khalid Al Marzooqi, Chief Executive Officer of Tabreed and Özgür Önder, Head of CVC Middle East, in the presence of Tabreed's Chairman, Dr Bakheet Al Katheeri.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store